
Indivior PLC (INDV) Stock Forecast & Price Target
Indivior PLC (INDV) Analyst Ratings
Bulls say
Indivior PLC's patient base for Sublocade treatment increased to approximately 171,500 in the third quarter of 2025, marking an 8% growth compared to the same quarter in 2024. The company has also seen a rise in prescribers of Sublocade, reaching about 8,568, which represents an 11% increase year-over-year. Furthermore, Indivior's upward revision of its 2025 revenue guidance for Sublocade, now estimated at $765 million to $786 million, reflects strong volume growth and the company's strategic focus on expanding its penetration in the Medicaid and commercial patient segments.
Bears say
Indivior PLC faces a challenging financial outlook primarily due to the expected decline in revenue from its key product, Suboxone, as a result of increasing generic competition. Although growth is anticipated from Sublocade in the long-acting injection (LAI) category, the company's overall revenue may not sufficiently offset the losses from Suboxone, especially considering unfavorable projections for subsequent quarters. Additionally, the forecasted selling, general, and administrative expenses (SG&A) will still constitute a significant portion of revenue, suggesting potential operational inefficiencies that could further pressure profitability.
This aggregate rating is based on analysts' research of Indivior PLC and is not a guaranteed prediction by Public.com or investment advice.
Indivior PLC (INDV) Analyst Forecast & Price Prediction
Start investing in Indivior PLC (INDV)
Order type
Buy in
Order amount
Est. shares
0 shares